Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

Core Viewpoint - Ocular Therapeutix, Inc. plans to release its first quarter 2025 financial results on May 5, 2025, at 7:00 AM Eastern Time, and will not hold a conference call for this quarter, resuming calls for the second quarter 2025 [1]. Company Overview - Ocular Therapeutix, Inc. is a biopharmaceutical company focused on redefining the retina experience [3]. - The company’s investigational product AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI) is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) [3]. - Ocular's pipeline includes DEXTENZA, an FDA-approved corticosteroid for treating ocular inflammation and pain post-surgery, and PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is in Phase 2 clinical trials for open-angle glaucoma or ocular hypertension [4].